Suppr超能文献

阿霉素敏感和耐药的P388白血病细胞系中DNA拓扑异构酶II活性与细胞毒性之间的直接相关性。

Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

作者信息

Deffie A M, Batra J K, Goldenberg G J

机构信息

Manitoba Institute of Cell Biology, Winnipeg, Canada.

出版信息

Cancer Res. 1989 Jan 1;49(1):58-62.

PMID:2535693
Abstract

The relationship between DNA topoisomerase II activity and drug resistance was studied in cloned cell lines of Adriamycin (ADR)-sensitive and -resistant P388 leukemia; drug resistant P388/ADR/3 (clone 3) and P388/ADR/7 (clone 7) cells are 5- and 10-fold more resistant to ADR than the sensitive cell line P388/4 (Cancer Res., 46: 2978, 1986). Topoisomerase II catalytic activity in crude nuclear extracts was reduced in drug-resistant cells as determined qualitatively by decatenation of kDNA. Using the centrifugal method fo quantitative analysis, topoisomerase II catalytic activity (mean +/- SE) was 81 +/- 10 units/mg total nuclear protein in sensitive cells, 29 +/- 2 units/mg total nuclear protein in resistant clone 3 cells, and 16 +/- 2 units/mg total nuclear protein in resistant clone 7 cells; these differences were highly significant (P less than 0.005). Similarly, quantitative analysis of DNA cleavage activity using 3' 32P-end-labeled pBR322 restriction fragments showed that drug-stimulated topoisomerase II cleavage activity in nuclear extracts from sensitive cells was approximately 1.7- and 2.9-fold greater than that from resistant clone 3 and 7 cells, respectively. Western blot analysis of nuclear extracts from the three cell lines using antibody against the C-terminal half of recombinant-prepared human topoisomerase II polypeptide revealed reduced immunoreactivity of topoisomerase II protein in the drug-resistant cells. These data suggest that reduced topoisomerase II activity in resistant cells, which may represent quantitative reduction of the enzyme, may be another property contributing to multifactorial drug resistance in these cells.

摘要

在阿霉素(ADR)敏感和耐药的P388白血病克隆细胞系中研究了DNA拓扑异构酶II活性与耐药性之间的关系;耐药的P388/ADR/3(克隆3)和P388/ADR/7(克隆7)细胞对ADR的耐药性分别比敏感细胞系P388/4高5倍和10倍(《癌症研究》,46: 2978, 1986)。通过kDNA解连环反应定性测定,耐药细胞中粗核提取物的拓扑异构酶II催化活性降低。采用离心法定量分析,敏感细胞中拓扑异构酶II催化活性(平均值±标准误)为81±10单位/毫克总核蛋白,耐药克隆3细胞中为29±2单位/毫克总核蛋白,耐药克隆7细胞中为16±2单位/毫克总核蛋白;这些差异具有高度显著性(P<0.005)。同样,使用3' 32P末端标记的pBR322限制性片段对DNA切割活性进行定量分析表明,敏感细胞核提取物中药物刺激的拓扑异构酶II切割活性分别比耐药克隆3和7细胞中的高约1.7倍和2.9倍。使用针对重组制备的人拓扑异构酶II多肽C末端一半的抗体对三种细胞系的核提取物进行蛋白质免疫印迹分析,结果显示耐药细胞中拓扑异构酶II蛋白的免疫反应性降低。这些数据表明,耐药细胞中拓扑异构酶II活性降低,这可能代表该酶的定量减少,可能是这些细胞多因素耐药的另一个原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验